Literature DB >> 34977909

Neuropsychiatric presentation of Covid-19-related encephalitis: Case report.

Marco Orsini1, Fábio Henrique de Gobbi Porto2, Jacqueline Fernandes do Nascimento3.   

Abstract

Covid-19-related encephalitis is a heterogeneous syndrome characterized by a combination of clinical, laboratory, and imaging features related to inflammation of the brain, where the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is presumably the causative agent. We reported a case of Covid-19-related encephalitis presenting with neuropsychiatric symptoms, including intense agitation. Reverse-transcriptase polymerase-chain-reaction in cerebrospinal fluid was positive for SARS-CoV-2. Our case expands the literature about neurologic manifestations of Covid-19 and emphasizes the possibility of prominent behavioral symptoms as the initial manifestation.
© 2021 The Authors.

Entities:  

Keywords:  Agitation; Covid-19-related encephalitis; Neuropsychiatric symptoms; SARS-CoV-2 infection

Year:  2021        PMID: 34977909      PMCID: PMC8552702          DOI: 10.1016/j.psycom.2021.100004

Source DB:  PubMed          Journal:  Psychiatry Res Commun        ISSN: 2772-5987


Introduction

Covid-19, the infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has a range of typical clinical manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia (Gandhi et al., 2020). Several neurologic manifestations have been described since late 2019, when a global pandemic started, increasing the burden of the disease (Asadi-pooya, 2020; Chen et al., 2021; Hassett et al., 2020). Neuropsychiatric manifestations have also been described, including a range of psychopathologies such as depression, anxiety, psychosis, suicidal ideation, insomnia, and delirium (Nalleballe et al., 2020; Taquet et al., 2021). Uncommon presentations of Covid-19 with encephalitis were recently reported (Pilotto et al., 2021), including limbic encephalitis (Bhagat et al., 2021; Chiveri et al., 2021). We report Covid-19-related encephalitis, confirmed by reverse-transcriptase polymerase-chain-reaction (RT-PCR) in cerebrospinal fluid (CSF), presenting with severe agitation.

Case report

A 52-year-old man was present in an outpatient neurologic office with a 3-day history of acute onset cognitive impairment characterized by impaired attention, forgetfulness, and difficulties with word-finding. Concomitantly, he developed aggressiveness and psychomotor agitation. He also had a new-onset generalized tonic-clonic seizure. He had contact with family members infected with Covid-19 in the previous 15 days. His past medical history was unremarkable. During the evaluation, the patient became agitated, with increased aimless motor activity and verbal and physical aggressiveness. He was unconcerned about the use of a facemask and became distressed when confronted by his family. During the office evaluation, he needed to be restricted to avoid aggression toward the physician. In-hospital investigation with 1.5T MRI revealed a normal-appearance brain imaging (including medial temporal lobe and other limbic structures - Fig. 1 ). CSF analysis showed a mild lymphocytic pleocytosis. CSF RT-PCR was positive for SARS-CoV-2 (Table 1 ). The electroencephalogram was normal. After a few days, cognitive impairment and neuropsychiatric features progressed. The patient evolved to a decreased level of consciousness. He developed dyspnea with rapid evolution to severe respiratory failure due to lung injury. The patient died due to pulmonary complications after three days of intensive care unit admission (10 days after the beginning of his illness). An autopsy was not performed.
Fig. 1

T2-weighted coronal MRI at the level of amygdalae (A) and hippocampal formations (B) showing typical appearing limbic structures.

Table 1

Cerebrospinal fluid panel results.

ParameterResultReference value
ColorColorlessColorless
AspectClearClear
Total proteins60 ​mg/dlAdults: 15–45 ​mg/dlAdults >60 anos: 15–60 ​mg/dl
Albumin22 ​mg/dl10–30 ​mg/dl
Glucose53 ​mg/dl50–80 ​mg/dl
Chlorides117 ​mmol/L115–130 ​mmol/l
LDH21 U/L0–25 U/L
Glutamine17 ​mg/dl15–20 ​mg/dl
Leukocytes8/μl0–5U/μl
Differential cytologyLymphocytes: 50%Monocytes: 12%Neutrophils: 4%Lymphocytes: 60% ​± ​20%Monocytes: 30% ​± ​15%Neutrophils: 2% ​± ​4%
Opening pressure120100–180
Cellularity8 cells/mm30-4 ​cells/mm3
VirusSars-Cov-2 PositiveNegative
MycobacteriaNegativeNegative
FungiNegativeNegative
ProtozoaNegativeNegative
SpirochetesNegativeNegative
T2-weighted coronal MRI at the level of amygdalae (A) and hippocampal formations (B) showing typical appearing limbic structures. Cerebrospinal fluid panel results.

Discussion

We reported a case of encephalitis due to Covid-19 with positive CSF RT-PCR for SARS-CoV-2, in which agitation was the first symptom. Encephalitis is characterized by a combination of clinical, laboratory, and imaging features related to brain inflammation (Graus et al., 2016). Proposed criteria for possible autoimmune encephalitis might be used as a guide for more general encephalitis and includes: 1) subacute onset (rapid progression of fewer than three months) of working memory deficits (short-term memory loss), altered mental status (defined as decreased or altered level of consciousness, lethargy, or personality change) or psychiatric symptoms; and 2) at least one of the following: new focal central nervous system (CNS) findings; seizures not explained by a previously known seizure disorder; CSF pleocytosis (white blood cell count of more than five cells per mm³; MRI features suggestive of encephalitis (Graus et al., 2016). According to this proposal, our patient fulfilled the criteria for possible encephalitis. The involvement of the central nervous system in SARS-CoV-2 is associated with a large spectrum of clinical syndromes, including encephalitis (Asadi-pooya, 2020; Hassett et al., 2020; Pilotto et al., 2021). In agreement with our case, most cases of encephalitis reported in a series of patients had normal MRI imaging (Pilotto et al., 2021). Despite significant neuropsychiatric symptomatology (agitation), neuroimaging was unremarkable in our case. However, normal imaging does not exclude CNS involvement of the SARS-CoV-2. Moreover, this clinical-radiologic paradox is frequently seen in the neurologic manifestations of COVID-19 (Jegatheeswaran et al., 2021; Kremer et al., 2020). Different from most cases of the same authors, our patient showed a positive CSF RT-PCR for SARS-CoV-2. Even with CNS involvement, positive CSF RT-PCR appears to be rare through the spectrum of CNS involvement of Covid-19 (Lewis et al., 2021; Placantonakis et al., 2020). However, CSF RT-PCR is the gold standard to detected CNS involvement in Covid-19 (Bellon et al., 2020). SARS-CoV-2 affects the brain through different mechanisms, including direct brain invasion inducing systemic pro-inflammatory cytokines that surpass the blood-brain barrier (cytokine storm). Also, neurotransmitter system dysfunction, brain vascular injury, thrombotic events, and neuronal damage are possible pathophysiologic events. All mechanisms may be associated with a myriad of neuropsychiatric symptoms (Boldrini et al., 2021). The finding of positive CSF RT-PCR in our patient is consistent with CNS direct invasion. Several mechanisms have been proposed, including penetration of the olfactory mucosa and transsynaptic migration along the olfactory tract, inflammation-induced breakdown of the blood-brain barrier or entrance via monocytes ("Trojan-horse" mechanism), or via circumventricular organs (midline structures around the third and fourth ventricles, where the capillaries have a wall devoid of the blood-brain barrier (Boldrini et al., 2021; Paterson et al., 2020; Zubair et al., 2020). Limbic system involvement probably occurs even in mild to moderate Covid-19 (Douaud et al., 2021). Limbic encephalitis was also reported (Bhagat et al., 2021; Chiveri et al., 2021). Proposed diagnostic criteria for limbic encephalitis require abnormal medial temporal lobe imaging (Graus et al., 2016), which was not present in the reported patient. Therefore, our case cannot be label as “limbic encephalitis. Nevertheless, the severe agitation presented by our patient possibly indicated the involvement of the limbic system (Cummings et al., 2015), even without imaging abnormalities in the limbic system, and is in line with other neuropsychiatric manifestations reported in the literature.

Conclusion

Covid-19 related encephalitis is a heterogeneous syndrome characterized by a combination of clinical, laboratory, and imaging features related to brain inflammation, where the SARS-CoV-2 is presumably the causative agent. As the pandemic persists and the number of infected subjects increases, knowledge about CNS involvement of the SARS-CoV-2 also increases. Our case report of COVID-19-related encephalitis presenting with prominent neuropsychiatric symptoms (agitation) and a positive CSF RT-PCR for SARS-CoV-2 expands the literature about the relationship between SARS-CoV-2 and CNS involvement.

Author statements

Marco Orsini: Conceptualization, Methodology; Data curation, Writing- Original draft preparation. Fábio Porto: Conceptualization, Methodology; Writing- Original draft,Writing- Reviewing and Editing. Jacqueline Fernandes do Nascimento: Writing- Original draft preparation.

Conflict of interest

The authors report no conflict of interest.
  19 in total

1.  How COVID-19 Affects the Brain.

Authors:  Maura Boldrini; Peter D Canoll; Robyn S Klein
Journal:  JAMA Psychiatry       Date:  2021-06-01       Impact factor: 21.596

2.  Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study.

Authors:  Stéphane Kremer; François Lersy; Mathieu Anheim; Hamid Merdji; Maleka Schenck; Hélène Oesterlé; Federico Bolognini; Julien Messie; Antoine Khalil; Augustin Gaudemer; Sophie Carré; Manel Alleg; Claire Lecocq; Emmanuelle Schmitt; René Anxionnat; François Zhu; Lavinia Jager; Patrick Nesser; Yannick Talla Mba; Ghazi Hmeydia; Joseph Benzakoun; Catherine Oppenheim; Jean-Christophe Ferré; Adel Maamar; Béatrice Carsin-Nicol; Pierre-Olivier Comby; Frédéric Ricolfi; Pierre Thouant; Claire Boutet; Xavier Fabre; Géraud Forestier; Isaure de Beaurepaire; Grégoire Bornet; Hubert Desal; Grégoire Boulouis; Jérome Berge; Apolline Kazémi; Nadya Pyatigorskaya; Augustin Lecler; Suzana Saleme; Myriam Edjlali-Goujon; Basile Kerleroux; Jean-Marc Constans; Pierre-Emmanuel Zorn; Muriel Mathieu; Seyyid Baloglu; François-Daniel Ardellier; Thibault Willaume; Jean-Christophe Brisset; Sophie Caillard; Olivier Collange; Paul Michel Mertes; Francis Schneider; Samira Fafi-Kremer; Mickael Ohana; Ferhat Meziani; Nicolas Meyer; Julie Helms; François Cotton
Journal:  Neurology       Date:  2020-07-17       Impact factor: 9.910

3.  Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition.

Authors:  Jeffrey Cummings; Jacobo Mintzer; Henry Brodaty; Mary Sano; Sube Banerjee; D P Devanand; Serge Gauthier; Robert Howard; Krista Lanctôt; Constantine G Lyketsos; Elaine Peskind; Anton P Porsteinsson; Edgardo Reich; Cristina Sampaio; David Steffens; Marc Wortmann; Kate Zhong
Journal:  Int Psychogeriatr       Date:  2014-10-14       Impact factor: 3.878

4.  The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings.

Authors:  Ross W Paterson; Rachel L Brown; Laura Benjamin; Ross Nortley; Sarah Wiethoff; Tehmina Bharucha; Dipa L Jayaseelan; Guru Kumar; Rhian E Raftopoulos; Laura Zambreanu; Vinojini Vivekanandam; Anthony Khoo; Ruth Geraldes; Krishna Chinthapalli; Elena Boyd; Hatice Tuzlali; Gary Price; Gerry Christofi; Jasper Morrow; Patricia McNamara; Benjamin McLoughlin; Soon Tjin Lim; Puja R Mehta; Viva Levee; Stephen Keddie; Wisdom Yong; S Anand Trip; Alexander J M Foulkes; Gary Hotton; Thomas D Miller; Alex D Everitt; Christopher Carswell; Nicholas W S Davies; Michael Yoong; David Attwell; Jemeen Sreedharan; Eli Silber; Jonathan M Schott; Arvind Chandratheva; Richard J Perry; Robert Simister; Anna Checkley; Nicky Longley; Simon F Farmer; Francesco Carletti; Catherine Houlihan; Maria Thom; Michael P Lunn; Jennifer Spillane; Robin Howard; Angela Vincent; David J Werring; Chandrashekar Hoskote; Hans Rolf Jäger; Hadi Manji; Michael S Zandi
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

Review 5.  Cerebrospinal fluid in COVID-19: A systematic review of the literature.

Authors:  Ariane Lewis; Jennifer Frontera; Dimitris G Placantonakis; Jennifer Lighter; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neurol Sci       Date:  2021-01-10       Impact factor: 3.181

6.  New-Onset Seizure With Possible Limbic Encephalitis in a Patient With COVID-19 Infection: A Case Report and Review.

Authors:  Riwaj Bhagat; Barbara Kwiecinska; Nolan Smith; Matthew Peters; Christopher Shafer; Adriana Palade; Vishwanath Sagi
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

7.  SARS-CoV-2 Is Not Detected in the Cerebrospinal Fluid of Encephalopathic COVID-19 Patients.

Authors:  Dimitris G Placantonakis; Maria Aguero-Rosenfeld; Abdallah Flaifel; John Colavito; Kenneth Inglima; David Zagzag; Matija Snuderl; Eddie Louie; Jennifer Ann Frontera; Ariane Lewis
Journal:  Front Neurol       Date:  2020-12-11       Impact factor: 4.003

8.  A systematic review of neurological symptoms and complications of COVID-19.

Authors:  Xiangliang Chen; Sarah Laurent; Finja Schweitzer; Clemens Warnke; Oezguer A Onur; Nina N Kleineberg; Gereon R Fink
Journal:  J Neurol       Date:  2020-07-20       Impact factor: 4.849

9.  Central nervous system manifestations of COVID-19: A systematic review.

Authors:  Ali A Asadi-Pooya; Leila Simani
Journal:  J Neurol Sci       Date:  2020-04-11       Impact factor: 3.181

10.  Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2-Related Encephalitis: The ENCOVID Multicenter Study.

Authors:  Andrea Pilotto; Stefano Masciocchi; Irene Volonghi; Massimo Crabbio; Eugenio Magni; Valeria De Giuli; Francesca Caprioli; Nicola Rifino; Maria Sessa; Michele Gennuso; Maria Sofia Cotelli; Marinella Turla; Ubaldo Balducci; Sara Mariotto; Sergio Ferrari; Alfonso Ciccone; Fabrizio Fiacco; Alberto Imarisio; Barbara Risi; Alberto Benussi; Enrico Premi; Emanuele Focà; Francesca Caccuri; Matilde Leonardi; Roberto Gasparotti; Francesco Castelli; Gianluigi Zanusso; Alessandro Pezzini; Alessandro Padovani
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

View more
  3 in total

1.  Response letter: Neuropsychiatric presentation of Covid-19-related encephalitis: Case report.

Authors:  Fábio Henrique de Gobbi Porto; Marco Orsini
Journal:  Psychiatry Res Commun       Date:  2022-02-28

2.  Seizure and neuropsychiatric compromise as onset of SARS-CoV-2 associated encephalitis.

Authors:  Josef Finsterer; Fulvio A Scorza
Journal:  Psychiatry Res Commun       Date:  2022-02-22

Review 3.  Encephalitis in Patients with COVID-19: A Systematic Evidence-Based Analysis.

Authors:  Md Asiful Islam; Cinzia Cavestro; Sayeda Sadia Alam; Shoumik Kundu; Mohammad Amjad Kamal; Faruque Reza
Journal:  Cells       Date:  2022-08-18       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.